Antemortem Markers

Principles and Practice of Geriatric Psychiatry: Third Edition

Volumn , Issue , 2010, Pages 299-303

  Van Rensburg, Susan J ^a   Potocnik, Felix C V ^b   Kotze, Maritha J ^b   Stein, Dan J ^c  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Acetylcholine; Behaviour; Cognition; Glutamate; Neurochemistry; Serotonin

Indexed keywords

EID: 84864762293     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470669600.ch51     Document Type: Chapter

References (42)

1. Zubenko GS. Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology 1992; 6: 77-93.
2. Roth M. Antemortem markers of Alzheimer's disease: a commentary. Neurobiol Aging 1986; 7: 402-5.
3. Perry EK, Tomlinson BE, Blessed G et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2: 1457-9.
4. Chalmers KA, Wilcock GK, Vinters HV et al. Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol 2009; 256(5): 717-20.
5. Wurtman RJ. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci 1992; 15(4): 117-22.
6. Marksteiner J, Pirchl M, Ullrich C et al. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties. Pharmacology 2008; 82(3): 214-20.
7. Kanof PD, Breenwald BS, Mohs RC, Davis KL. Red cell choline II: Kinetics in Alzheimer's disease. Biol Psychiatry 1985; 20(4): 375-83.
8. Haglund M, Sjöbeck M, Englund E. Locus ceruleus degeneration is ubiquitous in Alzheimer's disease: possible implications for diagnosis and treatment. Neuropathology 2006; 26(6): 528-32.
9. Stuerenburg HJ, Ganzer S, Müller-Thomsen T. 5-Hydroxyindoleacetic acid and homovanillic acid concentrations in cerebrospinal fluid in patients with Alzheimer's disease, depression and mild cognitive impairment. Neuro Endocrinol Lett 2004; 25(6): 435-7.
10. Mahlberg R, Walther S, Kalus P et al. Pineal calcification in Alzheimer's disease: an in vivo study using computed tomography. Neurobiol Aging 2008; 29(2): 203-9.
11. Wu YH, Swaab DF. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer's disease. Sleep Med 2007; 8(6): 623-36.
12. Uberti D, Lanni C, Racchi M, Govoni S, Memo M. Conformationally altered p53: a putative peripheral marker for Alzheimer's disease. Neurodegener Dis 2008; 5(3-4): 209-11.
13. Zainaghi IA, Forlenza OV, Gattaz WF. Abnormal APP processing in platelets of patients with Alzheimer's disease: correlations with membrane fluidity and cognitive decline. Psychopharmacology (Berl) 2007; 192(4): 547-53.
14. Zubenko GS, Winwood E, Jacobs B et al. Prospective study of risk factors for Alzheimer's disease: results at 7.5 years. Am J Psychiatry 1999; 156(1): 50-7.
15. Van Rensburg SJ, Daniels WMU, Van Zyl J et al. Lipid peroxidation and platelet membrane fluidity-implications for Alzheimer's disease? Neuroreport 1994; 5(17): 2221-4.
16. Etcheberrigaray R, Ito E, Oka K et al. Potassium channel dysfunction in fibroblasts identifies patients with Alzheimer's disease. Proc Natl Acad Sci U S A 1993; 90(17): 8209-13.
17. Ravid R. Biobanks for biomarkers in neurological disorders: the Da Vinci bridge for optimal clinico-pathological connection. J Neurol Sci 2009; 283(1): 119-26.
18. Maddalena A, Papassotiropoulos A, Müller-Tillmanns B et al. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to betaamyloid peptide42. Arch Neurol 2003; 60(9): 1202-6.
19. Tan ZS, Beiser AS, Vasan RS et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology 2007; 68(22): 1902-8.
20. Breitner JCS, Murphy EA, Folstein MF, Magruder-Habib K. Twin studies of Alzheimer's disease: an approach to etiology and prevention. Neurobiol Aging 1990; 11(6): 641-8.
21. Van Rensburg SJ, Van Zyl JM, Potocnik FCV et al. The effect of stress on the antioxidative potential of serum: implications for Alzheimer's disease. Metab Brain Dis 2006; 21(2-3): 171-9.
22. Desrosiers RR, Bertrand Y, Nguyen QT et al. Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease. Biochem J 2003; 374(2): 463-71.
23. Hock C, Drasch G, Golombowski S et al. Increased blood mercury levels in patients with Alzheimer's disease. J Neural Transm 1998; 105(1): 59-68.
24. Castellani RJ, Smith MA, Nunomura A, Harris PL, Perry G. Is increased redox-active iron in Alzheimer disease a failure of the copper-binding protein ceruloplasmin? Free Radic Biol Med 1999; 26(11-12): 1508-12.
25. Kessler H, Bayer TA, Bach D et al. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: a pilot phase 2 clinical trial. J Neural Transm 2008; 115(8): 1181-7.
26. Potocnik FC, Van Rensburg SJ, Hon D et al. Oral zinc augmentation with vitamins A and D increases plasma zinc concentration: implications for burden of disease. Metab Brain Dis 2006; 21(2-3): 139-47.
27. Wu J, Basha MR, Brock B et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 2008; 28(1): 3-9.
28. Hampel H, Bürger K, Teipel SJ et al. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 2008; 4(1): 38-48.
29. Weiner MW, Aisen PS, Jack CR Jr et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement 2010; 6(3): 202-11.e7.
30. Drzezga A, Grimmer T, Henriksen G et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009; 72(17): 1487-94.
31. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr Alzheimer Res 2009; 6(2): 137-43.
32. Li H, Wetten S, Li L et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008; 65: 45-53.
33. Kalaria RN, Maestre GE, Arizaga R et al. World Federation of Neurology Dementia Research Group. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol 2008; 7(9): 812-26.
34. Anttila T, Helkala EL, Viitanen M. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. Br Med J 2004; 329(7465): 539.
35. Van Rensburg SJ, Carstens ME, Potocnik FCV, Aucamp AK, Taljaard JJF. Increased frequency of the transferrin C2 subtype in Alzheimer's disease. Neuroreport 1993; 4(11): 1269-71.
36. Zambenedetti P, de Bellis G, Biunno I, Musicco M, Zatta P. Transferrin C2 variant does confer a risk for Alzheimer's disease in Caucasians. J Alzheimers Dis 2003; 5(6): 423-7.
37. Rondeau V, Iron A, Letenneur L et al. Analysis of the effect of aluminum in drinking water and transferrin C2 allele on Alzheimer's disease. Eur J Neurol 2006; 13(9): 1022-5.
38. Robson KJ, Lehmann DJ, Wimhurst VL et al. Synergy between the C2 allele of transferrin and the C282Y allele of the haemochromatosis gene (HFE) as risk factors for developing Alzheimer's disease. J Med Genet 2004; 41(4): 261-5.
39. Maes OC, Xu S, Yu B et al. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging 2007; 28(12): 1795-809.
40. Hye A, Lynham S, Thambisetty M et al. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006; 129(11): 3042-50.
41. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G; European Task Force Group. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol 2008; 7(5): 436-50.
42. Zellner M, Veitinger M, Umlauf E. The role of proteomics in dementia and Alzheimer's disease. Acta Neuropathol 2009; 118(1): 181-95